446 PUBLICATION A phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (pts) with HER-2-positive metastatic breast cancer (MBC)

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her 2 ◽

Phase II Trial with Gemcitabine, Paclitaxel and Bevacizumab for the First Line Treatment of Metastatic Breast Cancer.

10.1158/0008-5472.sabcs-09-6089 ◽

2009 ◽

Cited By ~ 2

Author(s):

A. Guardino ◽

M. Chen ◽

M. Levy ◽

C. Chen

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial.

10.1158/0008-5472.sabcs11-p5-19-03 ◽

2011 ◽

Cited By ~ 1

Author(s):

WJ Gradishar ◽

D Krasnojon ◽

S Cheporov ◽

AN Makhson ◽

GM Manikhas ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Abstract P5-17-05: Sorafenib plus Ixabepilone as First-Line Treatment for Patients with HER2-Negative Metastatic Breast Cancer: Preliminary Results of the Phase II Trial of the Sarah Cannon Research Institute

10.1158/0008-5472.sabcs12-p5-17-05 ◽

2012 ◽

Author(s):

DA Yardley ◽

J Barton ◽

N Dickson ◽

D Shipley ◽

DR Drosick ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Preliminary Results ◽

First Line Treatment ◽

Research Institute

A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer

Medical Oncology ◽

10.1007/s12032-010-9754-2 ◽

2010 ◽

Vol 28 (S1) ◽

pp. 142-151 ◽

Cited By ~ 3

Author(s):

M. Ghosn ◽

P. Aftimos ◽

F. S. Farhat ◽

J. G. Kattan ◽

C. Hanna ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Randomized Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Weekly Docetaxel ◽

Her 2 ◽

A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer

Cancer Investigation ◽

10.3109/07357907.2010.496755 ◽

2010 ◽

Vol 28 (9) ◽

pp. 925-931 ◽

Cited By ~ 14

Author(s):

Denise A. Yardley ◽

Michael McCleod ◽

Fred Schreiber ◽

Patrick Murphy ◽

Jeffrey Patton ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Activity and safety of vinorelbine and capecitabine as first-line treatment in patients with metastatic breast cancer – a phase II trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)70741-9 ◽

2008 ◽

Vol 6 (7) ◽

pp. 177 ◽

Cited By ~ 4

Author(s):

R. Palumbo ◽

A. Bernardo ◽

M. Strada ◽

C. Teragni ◽

G. Poggi ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First‐Line Treatment for HER‐2‐positive Locally Recurrent or Metastatic Breast Cancer

The Oncologist ◽

10.1634/theoncologist.2011-0344 ◽

2012 ◽

Vol 17 (4) ◽

pp. 469-475 ◽

Cited By ~ 34

Author(s):

Miguel Martín ◽

Anatoly Makhson ◽

Joseph Gligorov ◽

Mikhail Lichinitser ◽

Ana Lluch ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her 2 ◽

Locally Recurrent ◽

A Phase II Trial of Split, Low-Dose Docetaxel and Low-Dose Capecitabine: A Tolerable and Efficacious Regimen in the First-Line Treatment of Patients with HER2/neu–Negative Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.3816/cbc.2008.n.017 ◽

2008 ◽

Vol 8 (2) ◽

pp. 162-167 ◽

Cited By ~ 6

Author(s):

Orlando Silva ◽

Gilberto Lopes ◽

Daniel Morgenzstern ◽

Christopher Lobo ◽

Philomena Doliny ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Low Dose ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.1075 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 1075-1075 ◽

Cited By ~ 13

Author(s):

M. A. Danso ◽

J. L. Blum ◽

N. J. Robert ◽

L. Krekow ◽

R. Rotche ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.1032 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 1032-1032 ◽

Cited By ~ 2

Author(s):

N. W. Peacock ◽

J. R. Infante ◽

D. A. Yardley ◽

H. A. Burris ◽

F. A. Greco ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Weekly Docetaxel ◽